A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

被引：0
|
作者：
Darba, J. [1 ]
Restovic, G. [2 ]
Ramirez de Arellano, A. [3 ]
机构：
[1] Univ Barcelona, Barcelona, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
[3] Roche Farma SA, Madrid, Spain
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66563-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A467 / A467
页数：1
相关论文
共 50 条
  • [41] A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
    Jianguo Zhi
    Eric Chen
    Pierre Major
    Ivon Burns
    Bridget Robinson
    Joe McKendrick
    Karen Rittweger
    Markus Abt
    David Goldstein
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1199 - 1206
  • [42] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
    Zhi, Jianguo
    Chen, Eric
    Major, Pierre
    Burns, Ivon
    Robinson, Bridget
    McKendrick, Joe
    Rittweger, Karen
    Abt, Markus
    Goldstein, David
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1199 - 1206
  • [44] Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Sofya Pintova
    Sirish Dharmupari
    Erin Moshier
    Nicole Zubizarreta
    Celina Ang
    Randall F. Holcombe
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 591 - 598
  • [45] COST ANALYSIS OF METASTATIC COLORECTAL CANCER TREATMENT WITH BEVACIZUMAB AND CETUXIMAB
    Maria Vieitez, Jose
    Oyaguez, Itziar
    Angel Casado, Miguel
    ANNALS OF ONCOLOGY, 2011, 22 : v84 - v84
  • [46] COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL
    Caponero, R.
    Saggia, M. G.
    Nasciben, V. D.
    Santos, E. A.
    Stefani, S.
    VALUE IN HEALTH, 2008, 11 (06) : A474 - A475
  • [47] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Yiqi Zhuyu Decoction ((sic)) Combined with FOLFOX-4 as First-Line Therapy in Metastatic Colorectal Cancer
    Cao Bo
    Li Shao-tang
    Li Zhi
    Deng Wen-ling
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2011, 17 (08) : 593 - 599
  • [49] Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study
    Pintova, Sofya
    Dharmupari, Sirish
    Moshier, Erin
    Zubizarreta, Nicole
    Ang, Celina
    Holcombe, Randall F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 591 - 598
  • [50] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345